COMPANY OVERVIEW · NOVEMBER 2026

A Precision Neuroscience Platform

One biology. Three conditions.

CanaQuest

14 collaborators

CanaQuest is a precision neuroscience company developing CQ-001 for FDA approval as a prescription drug.

Epilepsy, TBI and Alzheimer's share biology. We target it, starting on an established route to approval.

THE HIDDEN LINK: THREE CONDITIONS, CONNECTED

15×	3×	1 in 10	1 of 14
more seizures in people with Alzheimer's	dementia risk after late-onset epilepsy	children develop epilepsy after a TBI	preventable dementia risks: TBI is one of them

Different diseases on the surface. Shared biology underneath. *Sources: Xu et al. (2021); Johnson et al. (2020); pediatric meta-analysis (2022); Lancet Commission (2024).*

ONE CORE FORMULATION, TWO LEAD CANDIDATES

Core formulation: an FDA-approved active ingredient (cannabidiol) + omega-3s DHA and EPA

Proprietary oral nanoemulsion · Dual-PPAR activation · four CanaQuest-owned patent families

LEAD CLINICAL CANDIDATE

CQ-001

Rare pediatric epilepsy

No approved drug for our target syndrome

Planned 505(b)(2)

Phase IIb ready in 18 months

LEAD PLATFORM DRUG CANDIDATE


CQ-001C Core plus proprietary additions · details under NDA

A second rare epilepsy	TBI, including concussion	Alzheimer's
First: validates the platform	**Extension:** no approved drug	**Extension:** ~100M living with symptoms

Four pillars: neuronal network regulation · mitochondrial support · neuroinflammation resolution · metabolic balance

Patient selection: biomarker-guided, building our Precision Patient Atlas

THE PROOF SO FAR: FROM DISCOVERY TO SEIZURE MODEL



~35% lower effective dose

About 1.5-fold potency vs. cannabidiol isolate, Epidiolex's active ingredient; two statistically significant experiments. Mouse seizure model, injected (CQ-001 will be oral); U of T, supported by OBI.

The discovery: at Western (Steven Laviolette, Ph.D.), each was ineffective alone at low doses; together, effective. Blocking PPARγ removed the effect.

WHY WE START WITH PEDIATRIC EPILEPSY


~50M living with epilepsy worldwide · **~36%** uncontrolled · **1 in 4** stop Epidiolex in real-world use

Lead where trials are smallest, signals cleanest, buyers exist. Our goal: seizure control for patients who can't tolerate higher doses of cannabidiol.

Paul Ramsay, Co-founder & CEO · paul@canaquest.com · +1 416-704-3040 · canaquest.com · Data room under NDA

This document contains forward-looking statements and is not an offer to buy or sell securities. Actual results may differ materially. Product candidates are investigational and not approved by the FDA, Health Canada or the EMA; preclinical results may not predict results in humans. Projections are management estimates; market data are from third-party sources not independently verified. Funding intentions are non-binding.

ONE STAGE 1. THREE READOUTS.



Inflammation IL-6, TNF-α

The body's "off switches" resolvins, made from omega-3s

Nerve-cell damage GFAP, NfL

Patient selection: biomarker-guided, with AI-assisted identification of likely responders.

Why it matters: one Stage 1 study generates data for all three conditions at once.

Why Stage 1 first: we select the patients most likely to respond before the larger clinical spend, so our trials start where the biology is strongest.

A PROVEN MARKET, WITH PLATFORM UPSIDE

LEAD PROGRAM: IN OUR PROJECTIONS			PLATFORM EXPANSION: BEYOND OUR PROJECTIONS		
~US$300M	**US$1B+**	**US$9.5B**	**None**	**US$400B**	**~100M**
North American sales within three years of approval	Epidiolex 2025 net sales	refractory epilepsy market, 2035	approved drug for TBI	global cost of TBI each year	living with symptomatic Alzheimer's

Acquirers have paid US$820M upfront to US$2.6B for rare-epilepsy drugs before approval. Each additional epilepsy indication builds on the first approval's safety and manufacturing package, as Epidiolex did across three epilepsy indications.

ROUTE, ECOSYSTEM AND LEVERAGE

Planned route: 505(b)(2), with Epidiolex as the Reference Listed Drug, to be confirmed with FDA at our pre-IND meeting. "A very realistic route to approval" (Dr. Hunter Land).

Ecosystem: 14 collaborators, including Western, U of T and OBI, the NRC, Charles River and Eurofins CDMO Alphora; plus SickKids Toronto, our intended Phase IIb site.

Capital leverage: Prevail Partners has stated it will fund about one-third of Phase IIb · IPON funds up to 80% of eligible IP costs.

LEADERSHIP AND ADVISORS

Leadership: Paul Ramsay, Co-founder & CEO (co-founded Cymat, TSX: CYM) · Ross Eastley, CPA, CA, Co-founder, CFO & Director (former VP & Controller, Brandon University) · Richard Rusiniak, Co-founder & Director · Cameron McDonald, MBA, CFA, Independent Director (formerly Canaccord Adams).

Scientific advisors: Dr. Hunter Land, Chief Scientific Advisor (Epidiolex development and approval) · Paul Dick, DVM, MSc, and Eddie Francis, MSc (development and commercialization).

IP counsel: David Heller, Smart & Biggar (all four patent families).

Sources: Jazz 10-K 2025; BIS Research; Lancet Neurol. 2017; Gustavsson 2022; WHO; Chen 2018; Epilepsy Behav. 2023.

Paul Ramsay, Co-founder & CEO · paul@canaquest.com · +1 416-704-3040 · canaquest.com

This document contains forward-looking statements and is not an offer to buy or sell securities. Actual results may differ materially. Product candidates are investigational and not approved by the FDA, Health Canada or the EMA; preclinical results may not predict results in humans. Projections are management estimates; market data are from third-party sources not independently verified. Funding intentions are non-binding.